Such rhetoric comes at a time when Pakistan is reeling from spiralling militancy, a collapsing economy, and widespread political turmoil.
According to the statement, the group’s operations target only “the Pakistan Army, Frontier Corps, intelligence networks, so-called death squads, and their collaborator gangs” inside Balochistan.
The BLA had already been classified as a Specially Designated Global Terrorist (SDGT) group by the US Treasury in 2019 after multiple high-profile terrorist attacks.
The incidents that were carried out over July 15-16 have reportedly left 29 soldiers dead, including a senior officer.
The attacks on Pakistani armed forces in Balochistan underscore the ongoing conflict in the region where separatists have waged a long-standing campaign for independence.
At least six people were killed in "coordinated" attacks in southwestern Pakistan, where gunmen targeted bus passengers based on ethnicity. Authorities suspect Baloch separatists, as violence surges amid ongoing insurgency in the resource-rich region.
A terrifying hijack unfolded in Pakistan as BLA’s Majeed Brigade seized the Jaffar Express, taking over 180 hostages, including military and intelligence officials. The attack led to intense clashes, with Pakistani forces launching a counter-operation. What was the motive behind this brazen assault? How did the security forces respond? Watch the full report to find out!
The attack began when the train was fired upon, causing it to become trapped inside a tunnel. Militants took control of the train after exchanging gunfire with security forces, which resulted in the driver being injured.
The driver was injured, and security personnel onboard engaged in a firefight, but the BLA seized control, claiming to hold over 182 passengers hostages, including military and ISI personnel.
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.